These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33767355)

  • 1. Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP) is associated with improvement in weight and components of metabolic syndrome in men exposed to androgen deprivation therapy for prostate cancer.
    Algotar AM; Hsu CH; Chow HH; Dougherty ST; Babiker HM; Marrero DG; Abraham I; Kumar R; Ligibel JA; Courneya KS; Smith TE; Jones PA; Lopez JN; Niemiro G; Ramakumar S; Hoy RD; Mack C; Thomson CA
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):903-909. PubMed ID: 33767355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP): Protocol for a Feasibility and Exploratory Efficacy Study in Men on Androgen Deprivation Therapy.
    Algotar A; Hsu CH; Sherry Chow HH; Dougherty S; Babiker HM; Marrero D; Abraham I; Kumar R; Ligibel J; Courneya KS; Thomson C
    JMIR Res Protoc; 2019 Feb; 8(2):e12579. PubMed ID: 30720441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
    Nobes JP; Langley SE; Klopper T; Russell-Jones D; Laing RW
    BJU Int; 2012 May; 109(10):1495-502. PubMed ID: 21933330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial.
    Freedland SJ; Howard L; Allen J; Smith J; Stout J; Aronson W; Inman BA; Armstrong AJ; George D; Westman E; Lin PH
    Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):428-437. PubMed ID: 30664736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.
    Harrington JM; Schwenke DC; Epstein DR; Bailey DE
    Oncol Nurs Forum; 2014 Jan; 41(1):21-9. PubMed ID: 24368236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protocol for a feasibility and early efficacy study of the Comprehensive Lifestyle Improvement Program for Prostate Cancer-2 (CLIPP2).
    Algotar AM; Kumar R; Babiker HM; Dougherty ST; Hsu CH; Chow HH; Smith TE; Marrero DG; Courneya KS; Abraham I; Ligibel JA; Thomson CA
    Contemp Clin Trials Commun; 2021 Mar; 21():100701. PubMed ID: 33511299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
    Braga-Basaria M; Dobs AS; Muller DC; Carducci MA; John M; Egan J; Basaria S
    J Clin Oncol; 2006 Aug; 24(24):3979-83. PubMed ID: 16921050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer.
    Mahalingam D; Hanni S; Serritella AV; Fountzilas C; Michalek J; Hernandez B; Sarantopoulos J; Datta P; Romero O; Pillai SMA; Kuhn J; Pollak M; Thompson IM
    Oncotarget; 2023 Jun; 14():622-636. PubMed ID: 37335291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Individualized Diet and Exercise Adherence Pilot Trial (IDEA-P) in prostate cancer patients undergoing androgen deprivation therapy: study protocol for a randomized controlled trial.
    Focht BC; Lucas AR; Grainger E; Simpson C; Thomas-Ahner JM; Clinton SK
    Trials; 2014 Sep; 15():354. PubMed ID: 25199619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility and Safety of Physical Exercise to Preserve Bone Health in Men With Prostate Cancer Receiving Androgen Deprivation Therapy: A Systematic Review.
    Cagliari M; Bressi B; Bassi MC; Fugazzaro S; Prati G; Iotti C; Costi S
    Phys Ther; 2022 Mar; 102(3):. PubMed ID: 34972863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
    Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
    Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a multi-component exercise programme and nutritional supplementation on musculoskeletal health in men treated with androgen deprivation therapy for prostate cancer (IMPACT): study protocol of a randomised controlled trial.
    Owen PJ; Daly RM; Livingston PM; Mundell NL; Dalla Via J; Millar JL; Fraser SF
    Trials; 2017 Oct; 18(1):451. PubMed ID: 28974267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.
    Grossmann M; Hamilton EJ; Gilfillan C; Bolton D; Joon DL; Zajac JD
    Med J Aust; 2011 Mar; 194(6):301-6. PubMed ID: 21426285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin for Prevention of Anthropometric and Metabolic Complications of Androgen Deprivation Therapy in Prostate Cancer Patients Receiving Radical Radiotherapy: A Phase II Randomized Controlled Trial.
    Usmani N; Ghosh S; Sanghera KP; Ong AD; Koul R; Dubey A; Ahmed S; Quon H; Yee D; Parliament M; Sivananthan G; Hunter W; Danielson B; Rowe L; McDonald M; Kim JO
    Int J Radiat Oncol Biol Phys; 2023 Feb; 115(2):317-326. PubMed ID: 35907513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mediterranean-style dietary pattern improves cancer-related fatigue and quality of life in men with prostate cancer treated with androgen deprivation therapy: A pilot randomised control trial.
    Baguley BJ; Skinner TL; Jenkins DG; Wright ORL
    Clin Nutr; 2021 Jan; 40(1):245-254. PubMed ID: 32534948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial.
    Bourke L; Gilbert S; Hooper R; Steed LA; Joshi M; Catto JW; Saxton JM; Rosario DJ
    Eur Urol; 2014 May; 65(5):865-72. PubMed ID: 24119318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of a Nurse-Led Mobile-Based Health Coaching Program for Patients With Prostate Cancer at High Risk of Metabolic Syndrome: Randomized Waitlist Controlled Trial.
    Lee K; Park J; Oh EG; Lee J; Park C; Choi YD
    JMIR Mhealth Uhealth; 2024 Feb; 12():e47102. PubMed ID: 38300697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving bone health in men with prostate cancer receiving androgen deprivation therapy: Results of a randomized phase 2 trial.
    Alibhai SMH; Breunis H; Timilshina N; Hamidi MS; Cheung AM; Tomlinson GA; Manokumar T; Samadi O; Sandoval J; Durbano S; Warde P; Jones JM
    Cancer; 2018 Mar; 124(6):1132-1140. PubMed ID: 29211305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications.
    Tzortzis V; Samarinas M; Zachos I; Oeconomou A; Pisters LL; Bargiota A
    Hormones (Athens); 2017 Apr; 16(2):115-123. PubMed ID: 28742500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Staying Strong and Healthy During Androgen Deprivation Therapy.
    Myers JS; Manson A; Billinger SA; Hamilton-Reeves J; Parker W; Maliski SL
    Cancer Nurs; 2024 Jan-Feb 01; 47(1):43-55. PubMed ID: 35984916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.